Ver el código de «Bisacodyl»

==Administration==
*Type: [[laxative]]
*Dosage Forms: tablet, enema, suppository
*Dosage Strengths: tablet: 5mg; enema: 10mg/30mL; suppository: 10mg
*Routes of Administration: PO, PR
*Common Trade Names: Dulcolax, Correctol, BisacEvac, Bisacolax, Codulax, Alophen, Feen A Mint, Fleet Stimulant Laxative, Laxit, Modane

==Adult Dosing==
*5-30mg PO daily
*10mg suppository daily

==Pediatric Dosing==
*6-11 yrs: 5mg or rectally daily
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: A
*[[Lactation risk categories|Lactation risk]]: infant risk cannot be ruled out
===Renal Dosing===
*Adult:
*Pediatric:
===Hepatic Dosing===
*Adult:
*Pediatric:

==Contraindications==
*Allergy to class/drug
*Appendicitis
*Bowel obstruction
*Gastroenteritis
==Adverse Reactions==
===Serious===
*Colonic atony
===Common===
*Abdominal discomfort/colic, diarrhea, proctitis (with suppository use)
==Pharmacology==
*Half-life: 8 hr
*Metabolism: Metabolized to BHPM in the colon
*Excretion: Urine and bile

==Mechanism of Action==
*Stimulates peristalsis via parasympathetic reflexes
==Comments==

==See Also==
*[[Constipation]]
==References==
*Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
*Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
*Christie J, Rose S. Constipation, diarrhea, hemorrhoids, and fecal incontinence. In: Pregnancy in gastrointestinal disorders. Bethesda (MD): ACG Monograph American College of Physicians; 2007. p. 4–9. Available at https://www.acg.gi.org
*Ducodyl (bisacodyl) [prescribing information]. Troy, MI: Prime Marketing; received January 2019.
*Friedrich C, Richter E, Trommeshauser D, et al, "Absence of Excretion of the Active Moiety of Bisacodyl and Sodium Picosulfate Into Human Breast Milk: An Open-Label, Parallel-Group, Multiple-Dose Study in Healthy Lactating Women," Drug Metab Pharmacokinet, 2011, 26(5):458-64. [PubMed 21697613]
*"Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics.1997;99(2):268-278. [PubMed 9024461]
*Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258-274. [PubMed 24345831]

<references/>
[[Category:Pharmacology]] [[Category:GI]]